<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:media="http://search.yahoo.com/mrss/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>patents &#8211; USA NEWS LIVE</title>
	<atom:link href="https://bloggingthree.soflytech.com/tag/patents/feed/" rel="self" type="application/rss+xml" />
	<link>https://bloggingthree.soflytech.com</link>
	<description>All About USA NEWS</description>
	<lastBuildDate>Thu, 04 Jul 2024 08:58:25 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://bloggingthree.soflytech.com/wp-content/uploads/2024/04/cropped-THE-USA1-e1713184454543-1-32x32.png</url>
	<title>patents &#8211; USA NEWS LIVE</title>
	<link>https://bloggingthree.soflytech.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>UN: China leads the race for generative AI patents; Tencent and Baidu top the list</title>
		<link>https://bloggingthree.soflytech.com/2024/07/un-china-leads-the-race-for-generative-ai-patents-tencent-and-baidu-top-the-list/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Thu, 04 Jul 2024 08:58:25 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[Baidu]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[generative]]></category>
		<category><![CDATA[leads]]></category>
		<category><![CDATA[list]]></category>
		<category><![CDATA[patents]]></category>
		<category><![CDATA[race]]></category>
		<category><![CDATA[Tencent]]></category>
		<category><![CDATA[top]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=8101</guid>

					<description><![CDATA[China dominates the worldwide race for patents on generative artificial intelligence, filing greater than 38,000 patents from 2014 to 2023, a brand new United Nations report on Thursday. That is six times greater than the variety of patents filed by inventors based within the United States, based on the United Nations World Intellectual Property Organization. [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody" data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p>China dominates the worldwide race for patents on generative artificial intelligence, filing greater than 38,000 patents from 2014 to 2023, a brand new <a href="https://news.un.org/en/story/2024/07/1151761" target="_blank" rel="noopener">United Nations report</a> on Thursday.</p>
<p>That is six times greater than the variety of patents filed by inventors based within the United States, based on the United Nations World Intellectual Property Organization.</p>
<p>Generative AI is a variety of artificial intelligence that enables users to generate content reminiscent of text, images, music, audio and videos.</p>
<p>Geographically, China leads the world with 38,210 inventions, far surpassing the United States (6,276), the Republic of Korea (4,155), Japan (3,409) and India (1,350).</p>
<p>According to the report, generative AI patents currently account for six% of all AI patents worldwide.</p>
<p>“The sharp increase in patent activity reflects recent technological advances and the potential of GenAI,” the report said.</p>
</div>
<div data-test="ArticleTable">
<section class="TableHeader-container" data-test="TableHeader" style="border-color:#002f6c">
<h3 class="TableHeader-themeTitle TableHeader-title">Top 10 Gen AI patent applicants from 2014 to 2023</h3>
</section>
<div>
<div class="BasicTable-basicTable" data-test="BasicTable">
<div class="BasicTable-tableWrapper">
<div class="BasicTable-articleContainer" style="border-color:#002f6c">
<table class="BasicTable-table">
<tbody class="BasicTable-tableBody">
<tr valign="middle">
<td class="BasicTable-textData"></td>
<td class="BasicTable-textData">Number of patents</td>
</tr>
<tr valign="middle">
<td class="BasicTable-textData">Tencent</td>
<td class="BasicTable-textData">2,074</td>
</tr>
<tr valign="middle">
<td class="BasicTable-textData">Ping An Insurance</td>
<td class="BasicTable-textData">1,564</td>
</tr>
<tr valign="middle">
<td class="BasicTable-textData">baidu</td>
<td class="BasicTable-textData">1,234</td>
</tr>
<tr valign="middle">
<td class="BasicTable-textData">Chinese Academy of Sciences</td>
<td class="BasicTable-numData">607</td>
</tr>
<tr valign="middle">
<td class="BasicTable-textData">IBM</td>
<td class="BasicTable-numData">601</td>
</tr>
<tr valign="middle">
<td class="BasicTable-textData">Alibaba Group</td>
<td class="BasicTable-numData">571</td>
</tr>
<tr valign="middle">
<td class="BasicTable-textData">Samsung Electronics</td>
<td class="BasicTable-numData">468</td>
</tr>
<tr valign="middle">
<td class="BasicTable-textData">alphabet</td>
<td class="BasicTable-numData">443</td>
</tr>
<tr valign="middle">
<td class="BasicTable-textData">ByteDance</td>
<td class="BasicTable-numData">418</td>
</tr>
<tr valign="middle">
<td class="BasicTable-textData">Microsoft</td>
<td class="BasicTable-numData">377</td>
</tr>
</tbody>
</table>
</div>
</div>
<p><i>Source: <!-- -->AND</i></p>
</div>
</div>
</div>
<div class="group">
<p>China has tried to meet up with ChatGPT owner OpenAI and US tech giants <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-2">Microsoft<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>, <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-3">alphabet<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>&#39;s Google and <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-4">Amazon<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    in the event of enormous language models (LLM), after joining late.</p>
<p><a href="https://openai.com/index/chatgpt/" target="_blank" rel="noopener">ChatGPT took the world by storm in November 2022</a> for its ability to generate human responses to user input.</p>
<p>Last 12 months, Chinese technology giants, including <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-6">Alibaba<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    And <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-7">baidu<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    have launched their very own LLMs to challenge their US counterparts.</p>
<p>To consolidate its presence in the worldwide technology race, <a href="https://english.www.gov.cn/news/202405/30/content_WS6657d8dcc6d0868f4e8e7a18.html" target="_blank" rel="noopener">China launched a three-year “action plan”</a> in May to strengthen standards in AI chips and generative AI and expand national computing power, with the aim of promoting technological and economic development.</p>
</div>
<div role="region" aria-labelledby="Placeholder-ArticleBody-Video-108001621">
<div role="button" tabindex="0" id="Placeholder-ArticleBody-Video-108001621" class="PlaceHolder-wrapper" data-vilynx-id="7000344808" data-test="VideoPlaceHolder">
<div class="InlineVideo-videoEmbed" id="InlineVideo-0" data-test="InlineVideo">
<div class="InlineVideo-wrapper">
<div class="InlineVideo-inlineThumbnailContainer"><img decoding="async" class="InlineVideo-videoThumbnail" src="https://image.cnbcfm.com/api/v1/image/108001622-17200602191720060214-35227106360-1080pnbcnews.jpg?v=1720060218&#038;w=750&#038;h=422&#038;vtcrop=y" alt="AI: Robotics is the ‘next frontier’ for both the US and China, says analyst"><span class="InlineVideo-videoButton"></span><span></span></div>
</div>
</div>
</div>
</div>
<div class="group">
<p>“China has [a] a huge untapped market for consumers and also for companies and industry partners to innovate and adopt generative AI technologies [in] different applications or industries that use different specialized data sets,&#8221; Wei Sun, senior artificial intelligence consultant at Counterpoint Research, told CNBC&#39;s &#8220;Street Signs Asia&#8221; on Thursday.</p>
<p>&#8220;This is the key to China&#39;s success, namely the development of real application implementations that could enable the country to surpass the United States in this area.&#8221;</p>
</div>
<div class="group">
<p>Image and video data dominated artificial intelligence patents with 17,996 inventions, followed by text (13,494) and speech or music (13,480), the UN report said.</p>
<p>By analyzing patent trends and data, the agency aims to help policymakers “shape the development of generic AI for our mutual benefit.”</p>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/108001620-1720059272753-gettyimages-2158375913-vcg111503079372.jpeg?v=1720059300&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
		<item>
		<title>The FTC is difficult &#8220;junk&#8221; patents from 10 drugmakers, including Novo Nordisk&#039;s Ozempic</title>
		<link>https://bloggingthree.soflytech.com/2024/05/the-ftc-is-difficult-junk-patents-from-10-drugmakers-including-novo-nordisks-ozempic/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Wed, 01 May 2024 07:20:35 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[challenging]]></category>
		<category><![CDATA[drugmakers]]></category>
		<category><![CDATA[FTC]]></category>
		<category><![CDATA[including]]></category>
		<category><![CDATA[junk]]></category>
		<category><![CDATA[Nordisk39s]]></category>
		<category><![CDATA[Novo]]></category>
		<category><![CDATA[Ozempic]]></category>
		<category><![CDATA[patents]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=2177</guid>

					<description><![CDATA[The Federal Trade Commission said Tuesday that this was the case difficult Hundreds of alleged “junk” patents that pharmaceutical firms consider cover 20 brand-name drugs, including Novo Nordisks Blockbuster drugs Ozempic, Saxenda and Victoza. The FTC sent letters to 10 firms warning them that certain drug patents weren&#8217;t properly listed. These firms include Novo Nordisk, [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody" data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p>The Federal Trade Commission said Tuesday that this was the case <a href="https://www.ftc.gov/news-events/news/press-releases/2024/04/ftc-expands-patent-listing-challenges-targeting-more-300-junk-listings-diabetes-weight-loss-asthma" target="_blank" rel="noopener">difficult</a> Hundreds of alleged “junk” patents that pharmaceutical firms consider cover 20 brand-name drugs, including <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-2">Novo Nordisks<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    Blockbuster drugs Ozempic, Saxenda and Victoza.</p>
<p>The FTC sent letters to 10 firms warning them that certain drug patents weren&#8217;t properly listed.  These firms include Novo Nordisk, <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-3">AstraZeneca<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>Boehringer Ingelheim, Covis Pharma, <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-4">GlaxoSmithKline<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>, <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-5">Novartis<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>, <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-6">Teva Pharmaceuticals<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    And <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-7">Amphastar Pharmaceuticals<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>and a few of its subsidiaries. </p>
<p>Many of the drug patents cover type 2 diabetes in addition to asthma and inhalers for chronic obstructive pulmonary disease (COPD). </p>
<p>Most top-selling drugs are protected by dozens of patents covering various ingredients, manufacturing processes, and mental property.  Generic drug manufacturers can only bring cheaper versions of a brand-name drug to market if the patents have expired or are successfully challenged in court.</p>
<p>“By filing fake patent applications, pharmaceutical companies block competition and increase the cost of prescription drugs, forcing Americans to pay exorbitant prices for the drugs they rely on,” FTC Chairwoman Lina Khan said in a press release.  “By challenging junk patent applications, the FTC combats these illegal tactics and ensures Americans have timely access to innovative and affordable versions of the medicines they need.”</p>
<p>The FTC also informed the Food and Drug Administration of the challenges.  The FDA maintains patent records for approved drugs in a document called the Orange Book.</p>
<p>The FTC first <a href="https://www.biopharmadive.com/news/ftc-orange-book-patent-advair-epipen-restasis/699132/" target="_blank" rel="noopener">challenged</a> Dozens of brand-name drug patents last fall, prompting three drugmakers to clear their patents with the FDA.  Five other firms didn&#8217;t. </p>
<p>Tuesday&#39;s announcement expands the Biden administration&#39;s efforts to crack down on alleged patent abuses by the pharmaceutical industry.  The FTC has argued that drugmakers are unnecessarily filing dozens of additional patents on brand-name drugs to maintain their drug prices high and deter generic competitors from entering the U.S. market. </p>
<p>The patent disputes complement the Biden administration&#39;s broader efforts to make health care more cost-effective for Americans &#8211; a key pillar of President Joe Biden&#39;s 2024 re-election campaign. </p>
<p>“We welcome the FTC’s collaboration with the FDA to crack down on Big Pharma’s patent games and reduce the cost of prescription drugs – including weight loss and diabetes drugs,” Jon Donenberg, deputy director of the National Economic Council, said in a press release Statement to CNBC.</p>
</div>
<div class="group">
<div class="RelatedContent-relatedContent" id="RegularArticle-RelatedContent-1">
<div class="RelatedContent-container">
<div class="RelatedContent-nonCollapsibleContent">
<h2 class="RelatedContent-header">Don&#39;t miss these exclusives from CNBC PRO</h2>
</div>
</div>
</div>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/107393000-17114709242023-11-18t105712z_413187213_rc2p34a9p2x4_rtrmadp_0_health-obesity-ozempic.jpeg?v=1711470985&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
	</channel>
</rss>
